Corbus Pharmaceuticals Holding (CRBP)

Corbus Pharmaceuticals Holdings, Inc. is a precision oncology company. The Company is engaged in developing and commercializing therapeutics for autoimmunity, fibrosis, and cancer. Its internal development pipeline includes CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells. It has developed CRB-913, a second-generation cannabinoid receptor type 1 (CB1) inverse agonist designed to treat obesity and related metabolic diseases. The CRB-913 program is in the pre-clinical-stage. It also includes Lenabasum, which is a novel, synthetic, oral molecule that selectively activates cannabinoid receptor type 2 (CB2) for the treatment of inflammation and fibrosis. Its subsidiaries include Corbus Pharmaceuticals, Inc., Corbus International Limited and Corbus Pharmaceuticals Australia Pty Ltd.